Navigation Links
NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium
Date:1/21/2011

-GT, which is expressed in the cells of lower mammals but not present in human or other Old World primate cells. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates, or α-Gal, on the surface of affected cells. Introducing α-Gal expressing cells to the human or primate immune system activates an immune response from antibodies against α-Gal. Antibodies directed against the α-Gal epitope are potentially the most abundant natural antibody in humans and represent approximately 1% of circulating human antibodies.

NewLink's HyperAcute cancer immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes α-Gal epitopes. This exposure to α-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on which α-Gal is present by activating complement, an important component of the immune system that is capable of cell destruction. After destruction, NewLink believes the resulting cellular fragments bound by anti-α-Gal antibodies are processed by the immune system to elicit an enhanced multifaceted immune response to tumorassociated antigens common to both the immunotherapy and the patient's tumor cells.

About HyperAcute Pancreas Immunotherapy

NewLink's HyperAcute Pancreas investigational product consists of equal doses of two separate allogeneic pancreatic cancer cell lines engineered to express α-Gal. Although cells making up naturally occurring pancreatic tumors in patients do not express α-Gal, the tumor cells share other molecules, called tumorspecific or tumorassociated antigens, with the genetically altered pancreatic cancer cells contained in HyperAcute Pancreas. NewLink believes the molecules that are common to a patient's tumor cells and HyperAcute Pancreas immunotherapy cells allow the antibodies and immu
'/>"/>

SOURCE NewLink Genetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NewLink Genetics Corporation Closes $7.5 Million Financing
2. NewLink Genetics to Present Phase 2 Data on HyperAcute(R)-Pancreas Immunotherapy at the American Society of Clinical Oncology Annual Meeting
3. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
4. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
5. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
6. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
7. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
8. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
9. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
10. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results
11. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... - Saying his higher education initiatives would increase the ... Jim Doyle has urged lawmakers to advance his ... has proposed the direct spending of $225 million to ... capabilities, and recruit more faculty members. The Legislature ...
... that patents and publications used to uphold a challenge to ... proliferation of human embryonic stem cells, the Wisconsin Alumni ... an initial determination by the U.S. Patent and Trademark ... Gulbrandsen, managing director of WARF, were supported by Dr. ...
... Madison, Wis. - Peter Logothetis pondered the ... concluded that it's part of a natural - and ... meet corporate objectives, to building strong working relationships with ... the business as well as information technology, the position ...
Cached Biology Technology:WARF questions relevancy of documents used to uphold patent challenge 2WARF questions relevancy of documents used to uphold patent challenge 3CIO Leadership Series: Logothetis likes CIO's evolving role 2CIO Leadership Series: Logothetis likes CIO's evolving role 3CIO Leadership Series: Logothetis likes CIO's evolving role 4CIO Leadership Series: Logothetis likes CIO's evolving role 5
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with ... device of Apple incorporating such a feature, called ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Acute lung injury caused by cell death, high and ... excess fluid in the lungs (pulmonary edema), may be ... researchers at Yale School of Medicine report in the ... study, which was completed in the laboratory of senior ...
... A first-of-its kind analysis of fifty years of remotely sensed ... in the size and number of more than 10,000 ponds ... and published this week in the Journal of Geophysical Research, ... with recent climate warming in Alaska and may have profound ...
... agent completely prevented the development of bone tumors in ... study, providing early evidence that it could treat, or ... for a number of cancers when they start to ... D. Anderson Cancer Center reported in the journal Cancer ...
Cached Biology News:Key to acute lung injury lies in Ang2 protein 2Shrinking ponds signal warmer, dryer Alaska 2'Trojan Horse' agent halts bone metastasis in mice 2'Trojan Horse' agent halts bone metastasis in mice 3